© 2020 MJH Life Sciences and Dermatology Times. All rights reserved.
Phase III under way
Feb 01, 2004, 5:00am
New York - Adjuvant therapy with a macrophage-activating growth factor appears to prolong survival in high-risk melanoma, Lynn E. Spitler, M.D., said.